Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

Patients treated with Xofigo-Xtandi experienced a 5.6-month boost to median OS over those treated with Xtandi alone.

Mayo Clinic in Jacksonville, Fla., offers a minimally invasive procedure to stabilize bones weakened by metastatic cancer, a technique available at few U.S. centers. The photodynamic bone ...

Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases ...

Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice? Bone metastases are a major cause of morbidity for men with prostate cancer. Complications of bone metastases include ...

SAN ANTONIO -- Prophylactic radiotherapy (RT) for asymptomatic bone metastases significantly reduced the rate of skeletal-related events (SREs) in patients with cancer, according to a small randomized ...

BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for patients with bone metastases from breast cancer, and also appeared to be ...

For patients with mCRPC with bone metastases, the addition of radium-223 to enzalutamide therapy is associated with improved overall survival.

In most cases, breast cancer with bone metastasis is incurable. Now, corresponding author Venu Raman, Ph.D., and his team say they have developed a potential novel treatment that is specific to breast ...

Rechallenge with trabectedin in patients with locally advanced or metastatic soft tissue sarcoma following drug holiday: The experience of the French Sarcoma Group (FSG). This is an ASCO Meeting ...

Case study demonstrated resolution of lytic lesions, significant reduction in pain and prevention of fracture. ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit ...

Radiation therapy treats roughly two-thirds of all cancer patients, yet healthy tissue has always absorbed collateral damage ...